ReviewNature reviews. Urology2012
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
Review in Nature reviews. Urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.Cancer · 2015Trial
- KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer.Molecular cancer · 2026Article
- Review
- Long-range gene regulation in hormone-dependent cancer.Nature reviews. Cancer · 2023Review
- mRNA-From COVID-19 Treatment to Cancer Immunotherapy.Biomedicines · 2023Review
- Graphdiyne Oxide-Mediated Photodynamic Therapy Boosts Enhancive T-Cell Immune Responses by Increasing Cellular Stiffness.International journal of nanomedicine · 2023Article
- Elimination of CD4Cell research · 2018Article
- Potentiating prostate cancer immunotherapy with oncolytic viruses.Nature reviews. Urology · 2018Review
- Article
- The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.Oncotarget · 2016Article
- Article
- Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.Southern medical journal · 2015Review
- Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14Oncoimmunology · 2014Article
- Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?Immunotherapy · 2013Review
- Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Review
- Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Prostate cancer and prostatic diseases · 2013Article
- Proposed mechanisms of action for prostate cancer vaccines.Nature reviews. Urology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by deleterious side effects. Immunotherapy represents a valuable alternative to conventional treatments by inducing tumour-specific immune responses that control the growth of cancer cells. Sipuleucel-T is approved by the FDA as an immunotherapeutic agent for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC). Although this approval has raised cost-versus-benefit issues, it has provided proof of concept for the therapeutic potential of active immunotherapy approaches for metastatic CRPC. Numerous clinical studies have demonstrated clinical benefit using immunotherapy compared to traditional chemotherapy and several active immunotherapy approaches (at various developmental stages)have demonstrated the potential to change the face of prostate cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.